Cartesian Therapeutics Q1 net loss $17.7M; cash $182.1M; Phase 3 AURORA on track

Cartesian Therapeutics, Inc.

2025-Q1 EPS reported -$0.68 revenue$1,100,000

Net loss of $17.7M ($0.68 basic loss per share) vs $56.8M ($10.50) in Q1 2024; R&D expenses rose to $14.7M.
Cash, equivalents and restricted cash $182.1M as of March 31, 2025; expected to fund operations into mid-2027.
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) expected to begin in Q2 2025 with ~100 participants.
Phase 2b data showed sustained MG-ADL reduction of 4.8 points at Month 12; deeper 7.1-point drop in biologic-naïve subgroup.
Preliminary Phase 2 SLE data and Phase 2 pediatric basket trial initiation expected in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.